The standard of care for HCV genotype 1 is a protease inhibitor (telaprevir or boceprevir) combined with pegylated interferon (PEG-IFN) and ribavirin (RBV). A lead-in phase of PEG-IFN/RBV therapy before addition of the protease inhibitor has been used, with the aim of improving response rates by reducing the development of protease inhibitor resistance. However, whether such a strategy can bring benefit to patients is unclear.
Methods
A viral dynamic model was used to compare in silico HCV dynamics in patients treated with a period of PEG-IFN/RBV lead-in therapy followed by the addition of a protease inhibitor versus immediate triple therapy without lead-in.
Results
The model predicts that both regimens result in a similar end-of-treatment viral load change (viral decline or breakthrough). Thus, the current lead-in strategy may not decrease the rate of viral breakthrough/relapse or increase the rate of sustained virological response. This agrees with available data from clinical trials of several HCV protease inhibitors, such as telaprevir, boceprevir and faldaprevir.
Conclusions
These results suggest that current PEG-IFN/RBV lead-in strategies may not improve treatment outcomes. However, viral kinetics during a period of PEG-IFN/RBV therapy, combined with other factors, such as the IL28B polymorphism and baseline viral load, can identify IFN-sensitive patients and help develop response-guided therapies.
References
1.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
2.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
3.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
4.
McHutchisonJ.G., EversonG.T., GordonS.C.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med2009; 360: 1827–1838.
5.
KwoP.Y., LawitzE.J., McConeJ.Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet2010; 376: 705–716.
6.
ZeuzemS., AndreoneP., PolS.Telaprevir for retreatment of HCV infection. N Engl J Med2011; 364: 2417–2428.
7.
PoordadF., McConeJ.Jr., BaconB.R.Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1195–1206.
8.
BaconB.R., GordonS.C., LawitzE.Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1207–1217.
9.
ShermanK.E., FlammS.L., AfdhalN.H.Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med2011; 365: 1014–1024.
10.
SulkowskiM.S., AsselahT., LalezariJ.Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology2013; 57: 2143–2154.
11.
SulkowskiM.S., BourliereM., BronowickiJ-PFaldaprevir combined with peginterferon alpha-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology2013; 57: 2155–2163.
12.
VierlingJ., PoordadF., LawitzE.Once daily narlaprevir (SCH 900518) in combination with peginterferon alfa-2b/ribavirin for treatment-naive patients with genotype-1 chronic hepatitis C: interim results from the NEXT-1 study. Hepatology2009; 50: 90A.
13.
OgertR.A., HoweJ.A., VierlingJ.M.Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther2013; 18: 387–397.
14.
FosterG.R., SerfatyL.D.Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: ‘lead-in or no lead-in'?Liver Int2012; 32Suppl 1: 61–63.
15.
RongL., DahariH., RibeiroR.M., PerelsonA.S.Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med2010; 2: 30–32.
16.
LindenbachB.D., RiceC.M.Unravelling hepatitis C virus replication from genome to function. Nature2005; 436: 933–938.
17.
NeumannA.U., LamN.P., DahariH.Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science1998; 282: 103–107.
18.
AdiwijayaB.S., HareB., CaronP.R.Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir Ther2009; 14: 591–595.
19.
FoyE., LiK., WangC.Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science2003; 300: 1145–1148.
20.
LiK., FoyE., FerreonJ.C.Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A2005; 102: 2992–2997.
21.
DixitN.M., Layden-AlmerJ.E., LaydenT.J., PerelsonA.S.Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature2004; 432: 922–924.
22.
DahariH., Affonso de AraujoE.S., HaagmansB.L.Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: Implications for treatment outcomes. J Hepatol2010; 53: 460–467.
23.
SnoeckE., ChanuP., LavielleM.A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther2010; 87: 706–713.
24.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology2007; 132: 1767–1777.
25.
KiefferT.L., SarrazinC., MillerJ.S.Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology2007; 46: 631–639.
26.
ZhouY., BartelsD.J., HanzelkaB.L.Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother2008; 52: 110–120.
27.
ZhouY., MuhU., HanzelkaB.L.Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem2007; 282: 22619–22628.
28.
RongL., RibeiroR.M., PerelsonA.S.Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol2012; 74: 1789–1817.
29.
RibeiroR.M., LiH., WangS.Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog2012; 8: e1002881.
30.
McHutchisonJ.G., MannsM.P., MuirA.J.Telaprevir for previously treated chronic HCV infection. N Engl J Med2010; 362: 1292–1303.
31.
AdiwijayaB.S., HerrmannE., HareB.A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLOS Comput Biol2010; 6: e1000745.
32.
AdiwijayaB.S., KiefferT.L., HenshawJ.A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLOS Comput Biol2012; 8: e1002339.
33.
ThomasD.L., ThioC.L., MartinM.P.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature2009; 461: 798–801.
34.
GeD., FellayJ., ThompsonA.J.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature2009; 461: 399–401.
35.
StättermayerA.F., StauberR., HoferH.Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol2011; 9: 344–350.
36.
ThompsonA.J., MuirA.J., SulkowskiM.S.Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology2010; 139: 120–129.
37.
PearlmanB.L., EhlebenC.Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology2014; 59: 71–77.
38.
DahariH., CotlerJ.S.Individualized treatment for patients with low HCV load (genotype 1): A viral kinetic approach. Hepatology2013; doi: 10.1002/hep.26772.
39.
FosterG.R., ZeuzemS., AndreoneP.Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol2013; 58: 488–494.
40.
OlsenD.B., DaviesM.E., HandtL.Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother2011; 55: 937–939.
41.
GaneE.J., RobertsS.K., StedmanC.A.Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet2010; 376: 1467–1475.
42.
ZeuzemS., SorianoV., AsselahT.Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med2013; 369: 630–639.
43.
GaneE.J., StedmanC.A., HylandR.H.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med2013; 368: 34–44.
44.
OsinusiA., MeissnerE.G., LeeY.J.Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA2013; 310: 804–811.
45.
WohnslandA., HofmannW.P., SarrazinC.Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev2007; 20: 23–38.
